Founders Grove Wealth Partners’s Novartis NVS Stock Holding History

Founders Grove Wealth Partners’s Portfolio NVS Stock Details NVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$225K	Buy	+1,471	New	+$225K	0.05%	152

Other funds holding NVS

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Founders Grove Wealth Partners's NVS Position: Q1 2026 in Review

Founders Grove Wealth Partners opened a new position in Novartis (NVS) in Q1 2026: 1,471 shares worth $225K. The stake represents 0.05% of the portfolio and ranks #152 among its holdings.

1,590 funds tracked by Wall St. Rank hold NVS as of Q1 2026.

Founders Grove Wealth Partners held 1,471 shares of Novartis worth $225K as of Q1 2026.
Novartis was a new Founders Grove Wealth Partners position in Q1 2026.
Novartis made up 0.05% of Founders Grove Wealth Partners's portfolio in Q1 2026, its #152 holding.
1,590 funds tracked by Wall St. Rank held Novartis as of Q1 2026.

Based on Founders Grove Wealth Partners's 13F filing for Q1 2026, filed 15 Apr 2026.